Francisco J. Esteva
dresteva.bsky.social
Francisco J. Esteva
@dresteva.bsky.social
Medical Oncologist specializing in breast cancer research and treatment. Opinions are my own. Not medical advice.

🎥 Start here: trusted cancer info
New videos weekly—subscribe below ⬇️
https://youtu.be/vcetk3Ixiv0?si=70_ooCr-9ytO2G6y
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer | NEJM
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or pro...
www.nejm.org
October 22, 2025 at 12:49 PM
🧬 Not everyone with breast cancer—or a family history—actually needs genetic testing. The real question is: how do you know if it’s the right step for you?

Take a look—you might be surprised by who doesn’t need testing, and who definitely should.

youtu.be/ctQZ8Fd7AAE?...
Should You Get Tested for Breast Cancer Genes?
YouTube video by Cancer Treatment Updates
youtu.be
September 25, 2025 at 10:59 PM
Cancer is overwhelming. But good information can change everything.

Each week, I share short, evidence-based videos on YouTube—breaking down the latest in treatment trends, side effect relief, and survivorship care.

youtu.be/vcetk3Ixiv0

#cancer #bcsm @ascopost.bsky.social @ascocancer.bsky.social
Fighting Cancer with Clarity & Hope | An Oncologist's Guide
YouTube video by Cancer Treatment Updates
youtu.be
June 24, 2025 at 7:47 PM
#ASCO25 trials suggest carboplatin may be safely omitted from neoadjuvant therapy in many HER2+ early breast cancers. neoCARHP showed non-inferior pCR without carboplatin and fewer side effects. CompassHER2-pCR confirmed strong THP efficacy, especially in ER− tumors.
#bcsm @ascocancer.bsky.social
June 3, 2025 at 1:43 PM
Are serial liquid biopsies finally ready for prime time?

If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.

That means #ctDNA won’t just monitor—it could guide treatment.

@ascocancer.bsky.social
#bcsm
June 1, 2025 at 11:46 PM
New hope for hormone-resistant breast cancer?
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯

@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
June 1, 2025 at 6:19 PM
Reposted by Francisco J. Esteva
@bsky.app more than adequately picked up what was lost from Twitter when it comes to medical conferences.
#sabcs24 was a throwback to those old days of following posts, seeing different perspectives on data, and seeing colleagues in San Antonio.
#hcsm has a new home. #oncsm #oncsky
December 14, 2024 at 11:33 AM
Just returned from #SABCS24—what an incredible experience! It was great reconnecting with old friends, making new connections, and immersing myself in the latest breakthroughs in breast cancer research and treatment. Events like this remind me how collaboration drives progress.
December 15, 2024 at 1:34 PM